Sign Up to like & get
recommendations!
0
Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-02454-5
Abstract: This study aimed to investigate the role of immunotrophic inflammatory markers in assessing the prognosis and treatment-related toxicity in patients with esophageal squamous cell carcinoma (ESCC) undergoing first-line radiotherapy and chemotherapy combined with immunotherapy. We…
read more here.
Keywords:
immunotrophic inflammatory;
escc undergoing;
group;
plr ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2022.2115926
Abstract: Abstract Background To assess the clinical value of serum complement component 1q (C1q) and immunoglobulin G (IgG) levels in predicting the response to combined immunotherapy in patients with esophageal squamous cell carcinoma. Methods We conducted…
read more here.
Keywords:
combined immunotherapy;
patients esophageal;
esophageal squamous;
immunotherapy patients ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-3952
Abstract: Optimal pairing of chemotherapy with immunotherapy can harness potential synergies and augment tumor immunity in solid tumors with low mutation burden by i) reducing tumor bulk, ii) releasing tumor antigen for cross-presentation and cross-priming, iii)…
read more here.
Keywords:
immunotherapy;
combined immunotherapy;
model;
breast cancer ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-pl2
Abstract: In 1995 Samuel Hellman and I advanced the hypothesis that many cancers represent a spectrum of disease from purely localized to widespread, highlighting a disease state we termed “oligometastasis.” We proposed that oligometastasis represented an…
read more here.
Keywords:
immunotherapy oligometastatic;
radiotherapy;
role radiotherapy;
cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "BMC Surgery"
DOI: 10.1186/s12893-025-02778-z
Abstract: Hepatocellular carcinoma (HCC) is a highly immunogenic tumor and the third leading cause of cancer-related deaths worldwide with an increasing incidence. Therefore, the combination of immunotherapy with other approaches, such as anti-angiogenic agents and local…
read more here.
Keywords:
rfa;
radiofrequency ablation;
hepatocellular carcinoma;
tumor ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of thoracic disease"
DOI: 10.21037/jtd-21-529
Abstract: Surgical treatment of locally advanced lung cancer is a major challenge in thoracic surgery. Neoadjuvant therapy has proven to be useful for tumor regression, while increasing surgical resection rates (1). Neoadjuvant chemotherapy combined with immunotherapy…
read more here.
Keywords:
chemotherapy combined;
lower lobectomy;
left lower;
neoadjuvant chemotherapy ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1106644
Abstract: Radiotherapy is one of the mainstays of cancer treatment. More than half of cancer patients receive radiation therapy. In addition to the well-known direct tumoricidal effect, radiotherapy has immunomodulatory properties. When combined with immunotherapy, radiotherapy,…
read more here.
Keywords:
multimodal radiotherapy;
application individualized;
hdrt;
radiotherapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2024.1479743
Abstract: Introduction This study examined the efficacy and safety of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer (MIBC). Methods This retrospective cohort study included patients diagnosed with MIBC at the First Affiliated…
read more here.
Keywords:
neoadjuvant chemotherapy;
chemotherapy;
efficacy;
chemotherapy combined ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2023.1051034
Abstract: Approximately 5% of advanced colorectal carcinomas (CRCs) and 12–15% of early CRCs are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Nowadays, PD-L1 inhibitors or combined CTLA4 inhibitors are the major strategies for advanced or…
read more here.
Keywords:
colorectal carcinomas;
combined immunotherapy;
risk factors;
case ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1072480
Abstract: The posterior line treatment of unresectable advanced or metastatic gastrointestinal (GI) tumors has always been a challenging point. In particular, for patients with microsatellite stable (MSS)/mismatch repair proficient (pMMR) 0GI tumors, the difficulty of treatment…
read more here.
Keywords:
therapy combined;
angiogenesis therapy;
therapy;
combined immunotherapy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10102528
Abstract: Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated…
read more here.
Keywords:
ipilimumab combined;
melanoma;
combined immunotherapy;
early effects ... See more keywords